2023 Fiscal Year Final Research Report
A study of appropriate target age of cancer screenings based on the balance of benefits and harms divided into life-stage
| Project/Area Number |
20K10331
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 58010:Medical management and medical sociology-related
|
|---|
| Research Institution | Teikyo University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | 遺伝性がん / サーベイランス / 利益不利益バランス / 診療ガイドライン / 科学的根拠 / 疾病登録 / 疾病負担 / Cost of Illness |
|---|
| Outline of Final Research Achievements |
Evidence-based guidelines and economic evaluation are required to establish surveillance of hereditary cancers. The following studies should be considered for guideline development due to lack of evidence: adoption of qualitative studies, systematic collection and utilization of experts’ opinions, development and efficient use of patient registry database, and extrapolation of indirect evidence on intermediate outcomes for prediction of final outcomes. Economic evaluation is also required, but the specific backgrounds of hereditary cancers should always be considered. The productivity loss of patients and their families and the burden on caregivers are necessary for the economic evaluation of hereditary cancers, which can have influence across patients’ lives. Cost of illness is a suitable economic approach for a comprehensive assessment. Based on these results, the balance of benefits and harms of surveillance for hereditary cancer should be appropriately evaluated.
|
| Free Research Field |
公衆衛生 医療技術評価 がん検診 診療ガイドライン作成 医療経済評価
|
| Academic Significance and Societal Importance of the Research Achievements |
遺伝子診断が拡大しハイリスク者の疾病管理が課題となるが、国際的にも遺伝性がんのサーベイランスは整っていない。リスクはあっても過剰なサーベイランスの提供は、健常者対象のがん検診と同様の不利益がある。遺伝性がんのサーベイランスの政策導入には、限られた科学的根拠を活用し、疾患特性に配慮したガイドラインの作成が必要である。また、医療経済の評価方法についても疾患の特異性を考慮し、患者・家族の負担を含めた評価が求められる。科学的根拠に基づくガイドラインの基本条件を明確化することで、遺伝性がんのサーベイランスについて、生涯にわたる利益不利益バランスを検討することが可能となる。
|
